ATE374612T1 - Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose - Google Patents

Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose

Info

Publication number
ATE374612T1
ATE374612T1 AT04707574T AT04707574T ATE374612T1 AT E374612 T1 ATE374612 T1 AT E374612T1 AT 04707574 T AT04707574 T AT 04707574T AT 04707574 T AT04707574 T AT 04707574T AT E374612 T1 ATE374612 T1 AT E374612T1
Authority
AT
Austria
Prior art keywords
progestin
endometriosis
estrogen
treatment
combination
Prior art date
Application number
AT04707574T
Other languages
English (en)
Inventor
Stephen Rubin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE374612T1 publication Critical patent/ATE374612T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04707574T 2003-02-05 2004-02-03 Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose ATE374612T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment

Publications (1)

Publication Number Publication Date
ATE374612T1 true ATE374612T1 (de) 2007-10-15

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04707574T ATE374612T1 (de) 2003-02-05 2004-02-03 Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose

Country Status (29)

Country Link
US (2) US7910570B2 (de)
EP (2) EP1589976B1 (de)
JP (2) JP4658918B2 (de)
KR (1) KR101075929B1 (de)
CN (1) CN100393360C (de)
AR (1) AR043013A1 (de)
AT (1) ATE374612T1 (de)
AU (1) AU2004210184B2 (de)
BR (1) BRPI0407039A (de)
CA (1) CA2513910C (de)
CO (1) CO5580789A2 (de)
CY (1) CY1107816T1 (de)
DE (1) DE602004009288T2 (de)
DK (1) DK1589976T3 (de)
ES (1) ES2293215T3 (de)
GB (1) GB0302572D0 (de)
IL (1) IL169583A0 (de)
IS (1) IS2547B (de)
MX (1) MXPA05008347A (de)
MY (1) MY140723A (de)
NO (1) NO20053626L (de)
NZ (1) NZ541222A (de)
PL (1) PL214680B1 (de)
PT (1) PT1589976E (de)
RU (2) RU2360681C2 (de)
TW (1) TWI354556B (de)
UA (1) UA80741C2 (de)
WO (1) WO2004069260A1 (de)
ZA (1) ZA200506221B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
CN101107004A (zh) * 2004-10-04 2008-01-16 韦恩州立大学 芳香酶抑制剂在子宫内膜腔和子宫手术前的子宫薄化中的应用
WO2009075838A2 (en) * 2007-12-10 2009-06-18 Meditrina Pharmaceuticals, Inc. Treatment of menorrhagia with aromatase inhibitor
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (de) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implantat mit einem Kern und einer den Kern umschliessenden Röhre
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko) 2022-11-22 2024-05-30 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물
US20240315958A1 (en) * 2023-03-23 2024-09-26 Chemo Research, S.L. Method and device for providing effective contraception
WO2024197239A1 (en) * 2023-03-23 2024-09-26 William Bologna Bioadhesive compositions and a method of treating endometriosis with aromatase inhibitors without increased gonadatroprin production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
PH30747A (en) * 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
TR200102867T2 (de) 1998-06-11 2002-06-21 Endorecherchel@Inc
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
DE60214355T2 (de) 2001-01-26 2007-08-30 Pfizer Italia S.R.L. Exemestan zur behandlung von hormonabhängigen störungen
WO2002074315A1 (de) 2001-03-21 2002-09-26 Schering Aktiengesellschaft Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017973A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
IL161630A0 (en) 2001-11-06 2004-09-27 Applied Research Systems Methods of treating endometreosis
JP2005518412A (ja) 2002-01-22 2005-06-23 アクゾ・ノベル・エヌ・ベー 内因性エストロゲンの合成を阻害する薬物の投与に伴う愁訴の治療におけるチボロン
AU2003213958A1 (en) 2002-04-03 2003-10-13 Jencap Research Ltd. Female birth control method
AU2003213956A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Improved hormone replacement therapy
CA2521305A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
JP2006516084A (ja) * 2002-06-27 2006-06-22 セントカー・インコーポレーテツド Ｃｎｇｈ０００４ポリペプチド、抗体、組成物、方法および使用
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
MY140723A (en) 2010-01-15
RU2360681C2 (ru) 2009-07-10
CA2513910A1 (en) 2004-08-19
ZA200506221B (en) 2006-05-31
EP1857111A2 (de) 2007-11-21
DE602004009288D1 (de) 2007-11-15
EP1589976B1 (de) 2007-10-03
CY1107816T1 (el) 2013-06-19
CN1747736A (zh) 2006-03-15
KR20050098296A (ko) 2005-10-11
EP1589976A1 (de) 2005-11-02
DE602004009288T2 (de) 2008-07-10
CA2513910C (en) 2012-04-03
KR101075929B1 (ko) 2011-10-26
IS2547B (is) 2009-10-15
US20110009373A1 (en) 2011-01-13
RU2008138166A (ru) 2010-03-27
CN100393360C (zh) 2008-06-11
TWI354556B (en) 2011-12-21
PL214680B1 (pl) 2013-09-30
TW200503731A (en) 2005-02-01
GB0302572D0 (en) 2003-03-12
NO20053626L (no) 2005-08-26
MXPA05008347A (es) 2005-11-04
CO5580789A2 (es) 2005-11-30
PL377939A1 (pl) 2006-02-20
RU2005127667A (ru) 2006-03-27
UA80741C2 (en) 2007-10-25
JP2011001388A (ja) 2011-01-06
US20060142256A1 (en) 2006-06-29
NZ541222A (en) 2008-12-24
HK1082918A1 (en) 2006-06-23
JP4658918B2 (ja) 2011-03-23
US7910570B2 (en) 2011-03-22
PT1589976E (pt) 2007-11-22
ES2293215T3 (es) 2008-03-16
BRPI0407039A (pt) 2006-01-17
WO2004069260A1 (en) 2004-08-19
IS8008A (is) 2005-08-30
JP2006516602A (ja) 2006-07-06
DK1589976T3 (da) 2007-12-27
EP1857111A3 (de) 2009-03-04
IL169583A0 (en) 2007-07-04
AU2004210184B2 (en) 2007-01-04
AU2004210184A1 (en) 2004-08-19
AR043013A1 (es) 2005-07-13

Similar Documents

Publication Publication Date Title
DE60216683D1 (de) Vorrichtung zur Verbesserung der Stabilität und des dynamischen Verhaltens eines Halbbrückenwandlers
ATE374612T1 (de) Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose
IL175858A0 (en) Extended use combination comprising estrogens and progestins
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE60221798D1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
DE602004017045D1 (de) Graduierte östrogen-kontrazeptiva
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE10107712B4 (de) Vorrichtung und Verfahren zur energetischen Nutzung von Faulschlammvergasungsgas
DE60332542D1 (de) Siliciumcarbid-einkristall und verfahren und vorrichtung zu seiner herstellung
DE60116652D1 (de) Eintauchausguss und verwendung dieser vorrichtung
ATE337787T1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
ATE522205T1 (de) Testosteronhaltiges transdermales therapeutisches system und verfahren zu seiner herstellung
EP1663283A4 (de) Glutamin zur verwendung bei der behandlung von verletzungen
ATE385789T1 (de) Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen
EP1610798A4 (de) Estradiolmetaboliten zur behandlung von lungenhochdruck
ATE205217T1 (de) Steroide als mittel zur kontrazeption und gegen osteoporose
DE50107458D1 (de) Verfahren und Vorrichtung zur Regelung des Parallelbetriebes von Gleichspannungswandlern
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE602004018921D1 (de) D dienogest
DE69934604D1 (de) Vorrichtung zur prüfung von kondomen
DE602004005748D1 (de) Nitrooxy-derivate von carvedilol und anderen betablockern als antihypertensiva
DE50110363D1 (de) Coniosetin und derivate davon, verfahren zur herstellung und verwendung derselben
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression
DE60208365D1 (de) Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1589976

Country of ref document: EP